Ibrutinib+rituximab vs. ibrutinib single agent vs. BR in TN elderly CLL patients (Alliance North American Intergroup Study A041202) (86); ibrutinib+rituximab vs. FCR in TN CLL patients with <70 years of age and no TP53 deletion/mutation (ECOG-ACRIN Cancer Research Group, E1912) (111); ibrutinib+G vs. G-Chl in TN CLL patients either elderly >65 years of age or young at high risk for unfitness or genetics (Illuminate PCYC-1130) (88). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.